Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells

Itaru Sato, Masanari Umemura, Kenji Mitsudo, Mitomu Kioi, Hideyuki Nakashima, Toshinori Iwai, Xianfeng Feng, Kayoko Oda, Akiyoshi Miyajima, Ayako Makino, Maki Iwai, Takayuki Fujita, Utako Yokoyama, Satoshi Okumura, Motohiko Sato, Haruki Eguchi, Iwai Tohnai, Yoshihiro Ishikawa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-45 °C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist®; superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5 °C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalJournal of Physiological Sciences
Volume64
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Mouth Neoplasms
Magnetic Fields
Cisplatin
Fever
Apoptosis
Induced Hyperthermia
Temperature
ferumoxides
Combination Drug Therapy
Neoplasms
Radiotherapy
Therapeutics
Iron
Magnetic Resonance Imaging
Drug Therapy
Incidence

Keywords

  • Anti-cancer effect
  • Cisplatin
  • Ferucarbotran
  • Hyperthermia
  • Oral cancer
  • Resovist®

ASJC Scopus subject areas

  • Physiology

Cite this

Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells. / Sato, Itaru; Umemura, Masanari; Mitsudo, Kenji; Kioi, Mitomu; Nakashima, Hideyuki; Iwai, Toshinori; Feng, Xianfeng; Oda, Kayoko; Miyajima, Akiyoshi; Makino, Ayako; Iwai, Maki; Fujita, Takayuki; Yokoyama, Utako; Okumura, Satoshi; Sato, Motohiko; Eguchi, Haruki; Tohnai, Iwai; Ishikawa, Yoshihiro.

In: Journal of Physiological Sciences, Vol. 64, No. 3, 01.01.2014, p. 177-183.

Research output: Contribution to journalArticle

Sato, I, Umemura, M, Mitsudo, K, Kioi, M, Nakashima, H, Iwai, T, Feng, X, Oda, K, Miyajima, A, Makino, A, Iwai, M, Fujita, T, Yokoyama, U, Okumura, S, Sato, M, Eguchi, H, Tohnai, I & Ishikawa, Y 2014, 'Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells', Journal of Physiological Sciences, vol. 64, no. 3, pp. 177-183. https://doi.org/10.1007/s12576-014-0309-8
Sato, Itaru ; Umemura, Masanari ; Mitsudo, Kenji ; Kioi, Mitomu ; Nakashima, Hideyuki ; Iwai, Toshinori ; Feng, Xianfeng ; Oda, Kayoko ; Miyajima, Akiyoshi ; Makino, Ayako ; Iwai, Maki ; Fujita, Takayuki ; Yokoyama, Utako ; Okumura, Satoshi ; Sato, Motohiko ; Eguchi, Haruki ; Tohnai, Iwai ; Ishikawa, Yoshihiro. / Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells. In: Journal of Physiological Sciences. 2014 ; Vol. 64, No. 3. pp. 177-183.
@article{30266035b27c452cbd42bcb153407ad8,
title = "Hyperthermia generated with ferucarbotran (Resovist{\circledR}) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells",
abstract = "Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-45 °C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist{\circledR}; superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5 °C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.",
keywords = "Anti-cancer effect, Cisplatin, Ferucarbotran, Hyperthermia, Oral cancer, Resovist{\circledR}",
author = "Itaru Sato and Masanari Umemura and Kenji Mitsudo and Mitomu Kioi and Hideyuki Nakashima and Toshinori Iwai and Xianfeng Feng and Kayoko Oda and Akiyoshi Miyajima and Ayako Makino and Maki Iwai and Takayuki Fujita and Utako Yokoyama and Satoshi Okumura and Motohiko Sato and Haruki Eguchi and Iwai Tohnai and Yoshihiro Ishikawa",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12576-014-0309-8",
language = "English (US)",
volume = "64",
pages = "177--183",
journal = "Journal of Physiological Sciences",
issn = "1880-6546",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells

AU - Sato, Itaru

AU - Umemura, Masanari

AU - Mitsudo, Kenji

AU - Kioi, Mitomu

AU - Nakashima, Hideyuki

AU - Iwai, Toshinori

AU - Feng, Xianfeng

AU - Oda, Kayoko

AU - Miyajima, Akiyoshi

AU - Makino, Ayako

AU - Iwai, Maki

AU - Fujita, Takayuki

AU - Yokoyama, Utako

AU - Okumura, Satoshi

AU - Sato, Motohiko

AU - Eguchi, Haruki

AU - Tohnai, Iwai

AU - Ishikawa, Yoshihiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-45 °C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist®; superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5 °C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.

AB - Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-45 °C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist®; superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5 °C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.

KW - Anti-cancer effect

KW - Cisplatin

KW - Ferucarbotran

KW - Hyperthermia

KW - Oral cancer

KW - Resovist®

UR - http://www.scopus.com/inward/record.url?scp=84901846525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901846525&partnerID=8YFLogxK

U2 - 10.1007/s12576-014-0309-8

DO - 10.1007/s12576-014-0309-8

M3 - Article

C2 - 24619404

AN - SCOPUS:84901846525

VL - 64

SP - 177

EP - 183

JO - Journal of Physiological Sciences

JF - Journal of Physiological Sciences

SN - 1880-6546

IS - 3

ER -